Researchers announce babies born from a trial of three-person IVF

Stay Ahead, Stay ONMINE

Researchers announce babies born from a trial of three-person IVF

Eight babies have been born in the UK thanks to a technology that uses DNA from three people: the two biological parents plus a third person who supplies healthy mitochondrial DNA. The babies were born to mothers who carry genes for mitochondrial diseases and risked passing on severe disorders. The eight babies are healthy, say the researchers behind the trial. “Mitochondrial disease can have a devastating impact on families,” Doug Turnbull of Newcastle University, one of the researchers behind the study, said in a statement. “Today’s news offers fresh hope to many more women at risk of passing on this condition, who now have the chance to have children growing up without this terrible disease.” The study, which makes use of a technology called mitochondrial donation, has been described as a “tour de force” and “a remarkable accomplishment” by others in the field. In the team’s approach, patients’ eggs are fertilized with sperm, and the DNA-containing nuclei of those cells are transferred into donated fertilized eggs that have had their own nuclei removed. The new embryos contain the DNA of the intended parents along with a tiny fraction of mitochondrial DNA from the donor, floating in the embryos’ cytoplasm. “The concept of [mitochondrial donation] has attracted much commentary and occasionally concern and anxiety,” Stuart Lavery, a consultant in reproductive medicine at University College Hospitals NHS Foundation Trust, said in a statement. “The Newcastle team have demonstrated that it can be used in a clinically effective and ethically acceptable way to prevent disease and suffering.” Not everyone sees the trial as a resounding success. While five of the children were born “with no health problems,” one developed a fever and a urinary tract infection, and another had muscle jerks. A third was treated for an abnormal heart rhythm. Three of the babies were born with a low level of the very mitochondrial-DNA mutations the treatment was designed to prevent. Heidi Mertes, a medical ethicist at Ghent University, says she is “moderately optimistic.” “I’m happy that it worked,” she says. “But at the same time, it’s concerning … it’s a call for caution and treading carefully.” Pavlo Mazur, a former embryologist who has used a similar approach in the conception of 15 babies in Ukraine, believes that trials like this one should be paused until researchers figure out what’s going on. Others believe that researchers should study the technique in people who don’t have mitochondrial mutations, to lower the risk of passing any disease-causing mutations to children. Long time coming The news of the births has been long awaited by researchers in the field. Mitochondrial donation was first made legal in the UK in 2015. Two years later, the Human Fertility and Embryology Authority (HFEA), which regulates fertility treatment and research in the UK, granted a fertility clinic in Newcastle the sole license to perform the procedure. Newcastle Fertility Centre at Life launched a trial of mitochondrial donation in 2017 with the aim of treating 25 women a year. That was eight years ago. Since then, the Newcastle team have been extremely tight-lipped about the trial. That’s despite the fact that other teams elsewhere have used mitochondrial donation to help people achieve pregnancy. A New York–based doctor used a type of mitochondrial donation to help a Jordanian couple conceive in Mexico in 2016. Mitochondrial donation has also been trialed by teams in Ukraine and Greece. But as the only trial overseen by the HFEA, the Newcastle team’s study was viewed by many as the most “official.” Researchers have been itching to hear how the work has been going, given the potential implications for researchers elsewhere (mitochondrial donation was officially made legal in Australia in 2022). “I’m very glad to see [the results] come out at last,” says Dagan Wells, a reproductive biologist at the University of Oxford who worked on the Greece trial. “It would have been nice to have some information out along the way.” At the Newcastle clinic, each patient must receive approval from the HFEA to be eligible for mitochondrial donation. Since the trial launched in 2017, 39 patients have won this approval. Twenty-five of them underwent hormonal stimulation to release multiple eggs that could be frozen in storage. Nineteen of those women went on to have mitochondrial donation. So far, seven of the women have given birth (one had twins), and an eighth is still pregnant. The oldest baby is two years old. The results were published today in the New England Journal of Medicine. “As parents, all we ever wanted was to give our child a healthy start in life,” one of the mothers, who is remaining anonymous, said in a statement. “Mitochondrial donation IVF made that possible. After years of uncertainty this treatment gave us hope—and then it gave us our baby … Science gave us a chance.” When each baby was born, the team collected a blood and urine sample to look at the child’s mitochondrial DNA. They found that the levels of mutated DNA were far lower than they would have expected without mitochondrial donation. Three of the mothers were “homoplasmic”—100% of their mitochondrial DNA carried the mutation. But blood tests showed that in the women’s four babies (including the twins), 5% or less of the mitochondrial DNA had the mutation, suggesting they won’t develop disease. A mixed result The researchers see this as a positive result. “Children who would otherwise have inherited very high levels are now inheriting levels that are reduced by 77% to 100%,” coauthor Mary Herbert, a professor of reproductive biology at Newcastle University and Monash University, told me during a press briefing. But three of the eight babies had health symptoms. At seven months, one was diagnosed with a rare form of epilepsy, which seemed to resolve within the following three months. Another baby developed a urinary tract infection. A third baby developed “prolonged” jaundice, high levels of fat in the blood, and a disturbed heart rhythm that required treatment. The baby seemed to have recovered by 18 months, and doctors believe that the symptoms were not related to the mitochondrial mutations, but the team members admit that they can’t be sure. Given the small sample size, it’s hard to make comparisons with babies conceived in other ways. And they acknowledge that a phenomenon called “reversal” is happening in some of the babies. In theory, the children shouldn’t inherit any “bad” mitochondrial DNA from their mothers. But three of them did. The levels of “bad” mitochondrial DNA in the babies’ blood ranged between 5% and 16%. And they were higher in the babies’ urine—the highest figure being 20%. The researchers don’t know why this is happening. When an embryologist pulls out the nucleus of a fertilized egg, a bit of mitochondria-containing cytoplasm will inevitably be dragged along with it. But the team didn’t see any link between the amount of carried-over cytoplasm and the level of “bad” mitochondria. “We continue to investigate this issue,” Herbert said. “As long as they don’t understand what’s happening, I would still be worried,” says Mertes. Such low levels aren’t likely to cause mitochondrial diseases, according to experts contacted by MIT Technology Review. But some are concerned that the percentage of mutated DNA could be higher in different tissues, such as the brain or muscle, or that the levels might change with age. “You never know which tissues [reversal] will show up in,” says Mazur, who has seen the phenomenon in babies born through mitochondrial donation to parents who didn’t have mitochondrial mutations. “It’s chaotic.” The Newcastle team says it hasn’t looked at other tissues, because it designed the study to be noninvasive. There has been at least one case in which similar levels of “bad” mitochondria have caused symptoms, says Joanna Poulton, a mitochondrial geneticist at the University of Oxford. She thinks it’s unlikely that the children in the trial will develop any symptoms but adds that “it’s a bit of a worry.” The age of reversal No one knows exactly when this reversal happens. But Wells and his colleagues have some idea. In their study in Greece, they looked at the mitochondrial DNA of embryos and checked them again during pregnancy and after birth. The trial was designed to study the impact of mitochondrial donation for infertility—none of the parents involved had genes for mitochondrial disease. The team has seen mitochondrial reversal in two of the seven babies born in the trial, says Wells. If you put the two sets of results together, mitochondrial donation “seems to have this possibility of reversal occurring in maybe about a third of children,” he says. In his study, the reversal seemed to occur early on in the embryos’ development, Wells says. Five-day-old embryos “look perfect,” but mitochondrial mutations start showing up in tests taken at around 15 weeks of pregnancy, he says. After that point, the levels appear to be relatively stable. The Newcastle researchers say they will monitor the children until they are five years old. People enrolling in future trials might opt for amniocentesis, which involves sampling blood from the fetus’s amniotic sac at around 15 to 18 weeks, suggests Mertes. That test might reveal the likely level of mitochondrial mutations in the resulting child. “Then the parents could decide what to do,” says Mertes. “If you could see there was a 90% mutation load [for a] very serious mitochondrial disease, they would still have an option to cancel the pregnancy,” she says. Wells thinks the Newcastle team’s results are “generally reassuring.” He doesn’t think the trials should be paused. But he wants people to understand that mitochondrial donation is not without risk. “This can only be viewed as a risk reduction strategy, and not a guarantee of having an unaffected child,” he says. And, as Mertes points out, there’s another option for women who carry mitochondrial DNA mutations: egg donation. Donor eggs fertilized with a partner’s sperm and transferred to a woman’s uterus won’t have her disease-causing mitochondria. That option won’t appeal to people who feel strongly about having a genetic link to their children. But Poulton asks: “If you know whose uterus you came out of, does it matter that the [egg] came from somewhere else?”

“Mitochondrial disease can have a devastating impact on families,” Doug Turnbull of Newcastle University, one of the researchers behind the study, said in a statement. “Today’s news offers fresh hope to many more women at risk of passing on this condition, who now have the chance to have children growing up without this terrible disease.”

The study, which makes use of a technology called mitochondrial donation, has been described as a “tour de force” and “a remarkable accomplishment” by others in the field. In the team’s approach, patients’ eggs are fertilized with sperm, and the DNA-containing nuclei of those cells are transferred into donated fertilized eggs that have had their own nuclei removed. The new embryos contain the DNA of the intended parents along with a tiny fraction of mitochondrial DNA from the donor, floating in the embryos’ cytoplasm.

“The concept of [mitochondrial donation] has attracted much commentary and occasionally concern and anxiety,” Stuart Lavery, a consultant in reproductive medicine at University College Hospitals NHS Foundation Trust, said in a statement. “The Newcastle team have demonstrated that it can be used in a clinically effective and ethically acceptable way to prevent disease and suffering.”

Not everyone sees the trial as a resounding success. While five of the children were born “with no health problems,” one developed a fever and a urinary tract infection, and another had muscle jerks. A third was treated for an abnormal heart rhythm. Three of the babies were born with a low level of the very mitochondrial-DNA mutations the treatment was designed to prevent.

Heidi Mertes, a medical ethicist at Ghent University, says she is “moderately optimistic.” “I’m happy that it worked,” she says. “But at the same time, it’s concerning … it’s a call for caution and treading carefully.”

Pavlo Mazur, a former embryologist who has used a similar approach in the conception of 15 babies in Ukraine, believes that trials like this one should be paused until researchers figure out what’s going on. Others believe that researchers should study the technique in people who don’t have mitochondrial mutations, to lower the risk of passing any disease-causing mutations to children.

Long time coming

The news of the births has been long awaited by researchers in the field. Mitochondrial donation was first made legal in the UK in 2015. Two years later, the Human Fertility and Embryology Authority (HFEA), which regulates fertility treatment and research in the UK, granted a fertility clinic in Newcastle the sole license to perform the procedure. Newcastle Fertility Centre at Life launched a trial of mitochondrial donation in 2017 with the aim of treating 25 women a year.

That was eight years ago. Since then, the Newcastle team have been extremely tight-lipped about the trial. That’s despite the fact that other teams elsewhere have used mitochondrial donation to help people achieve pregnancy. A New York–based doctor used a type of mitochondrial donation to help a Jordanian couple conceive in Mexico in 2016. Mitochondrial donation has also been trialed by teams in Ukraine and Greece.

But as the only trial overseen by the HFEA, the Newcastle team’s study was viewed by many as the most “official.” Researchers have been itching to hear how the work has been going, given the potential implications for researchers elsewhere (mitochondrial donation was officially made legal in Australia in 2022). “I’m very glad to see [the results] come out at last,” says Dagan Wells, a reproductive biologist at the University of Oxford who worked on the Greece trial. “It would have been nice to have some information out along the way.”

At the Newcastle clinic, each patient must receive approval from the HFEA to be eligible for mitochondrial donation. Since the trial launched in 2017, 39 patients have won this approval. Twenty-five of them underwent hormonal stimulation to release multiple eggs that could be frozen in storage.

Nineteen of those women went on to have mitochondrial donation. So far, seven of the women have given birth (one had twins), and an eighth is still pregnant. The oldest baby is two years old. The results were published today in the New England Journal of Medicine.

“As parents, all we ever wanted was to give our child a healthy start in life,” one of the mothers, who is remaining anonymous, said in a statement. “Mitochondrial donation IVF made that possible. After years of uncertainty this treatment gave us hope—and then it gave us our baby … Science gave us a chance.”

When each baby was born, the team collected a blood and urine sample to look at the child’s mitochondrial DNA. They found that the levels of mutated DNA were far lower than they would have expected without mitochondrial donation. Three of the mothers were “homoplasmic”—100% of their mitochondrial DNA carried the mutation. But blood tests showed that in the women’s four babies (including the twins), 5% or less of the mitochondrial DNA had the mutation, suggesting they won’t develop disease.

A mixed result

The researchers see this as a positive result. “Children who would otherwise have inherited very high levels are now inheriting levels that are reduced by 77% to 100%,” coauthor Mary Herbert, a professor of reproductive biology at Newcastle University and Monash University, told me during a press briefing.

But three of the eight babies had health symptoms. At seven months, one was diagnosed with a rare form of epilepsy, which seemed to resolve within the following three months. Another baby developed a urinary tract infection.

A third baby developed “prolonged” jaundice, high levels of fat in the blood, and a disturbed heart rhythm that required treatment. The baby seemed to have recovered by 18 months, and doctors believe that the symptoms were not related to the mitochondrial mutations, but the team members admit that they can’t be sure. Given the small sample size, it’s hard to make comparisons with babies conceived in other ways.

And they acknowledge that a phenomenon called “reversal” is happening in some of the babies. In theory, the children shouldn’t inherit any “bad” mitochondrial DNA from their mothers. But three of them did. The levels of “bad” mitochondrial DNA in the babies’ blood ranged between 5% and 16%. And they were higher in the babies’ urine—the highest figure being 20%.

The researchers don’t know why this is happening. When an embryologist pulls out the nucleus of a fertilized egg, a bit of mitochondria-containing cytoplasm will inevitably be dragged along with it. But the team didn’t see any link between the amount of carried-over cytoplasm and the level of “bad” mitochondria. “We continue to investigate this issue,” Herbert said.

“As long as they don’t understand what’s happening, I would still be worried,” says Mertes.

Such low levels aren’t likely to cause mitochondrial diseases, according to experts contacted by MIT Technology Review. But some are concerned that the percentage of mutated DNA could be higher in different tissues, such as the brain or muscle, or that the levels might change with age. “You never know which tissues [reversal] will show up in,” says Mazur, who has seen the phenomenon in babies born through mitochondrial donation to parents who didn’t have mitochondrial mutations. “It’s chaotic.”

The Newcastle team says it hasn’t looked at other tissues, because it designed the study to be noninvasive.

There has been at least one case in which similar levels of “bad” mitochondria have caused symptoms, says Joanna Poulton, a mitochondrial geneticist at the University of Oxford. She thinks it’s unlikely that the children in the trial will develop any symptoms but adds that “it’s a bit of a worry.”

The age of reversal

No one knows exactly when this reversal happens. But Wells and his colleagues have some idea. In their study in Greece, they looked at the mitochondrial DNA of embryos and checked them again during pregnancy and after birth. The trial was designed to study the impact of mitochondrial donation for infertility—none of the parents involved had genes for mitochondrial disease.

The team has seen mitochondrial reversal in two of the seven babies born in the trial, says Wells. If you put the two sets of results together, mitochondrial donation “seems to have this possibility of reversal occurring in maybe about a third of children,” he says.

In his study, the reversal seemed to occur early on in the embryos’ development, Wells says. Five-day-old embryos “look perfect,” but mitochondrial mutations start showing up in tests taken at around 15 weeks of pregnancy, he says. After that point, the levels appear to be relatively stable. The Newcastle researchers say they will monitor the children until they are five years old.

People enrolling in future trials might opt for amniocentesis, which involves sampling blood from the fetus’s amniotic sac at around 15 to 18 weeks, suggests Mertes. That test might reveal the likely level of mitochondrial mutations in the resulting child. “Then the parents could decide what to do,” says Mertes. “If you could see there was a 90% mutation load [for a] very serious mitochondrial disease, they would still have an option to cancel the pregnancy,” she says.

Wells thinks the Newcastle team’s results are “generally reassuring.” He doesn’t think the trials should be paused. But he wants people to understand that mitochondrial donation is not without risk. “This can only be viewed as a risk reduction strategy, and not a guarantee of having an unaffected child,” he says.

And, as Mertes points out, there’s another option for women who carry mitochondrial DNA mutations: egg donation. Donor eggs fertilized with a partner’s sperm and transferred to a woman’s uterus won’t have her disease-causing mitochondria.

That option won’t appeal to people who feel strongly about having a genetic link to their children. But Poulton asks: “If you know whose uterus you came out of, does it matter that the [egg] came from somewhere else?”

Stay Ahead

Explore More Insights

Stay ahead with more perspectives on cutting-edge power, infrastructure, energy, bitcoin and AI solutions. Explore these articles to uncover strategies and insights shaping the future of industries.

Chain of Thought Monitorability: A New and Fragile Opportunity for AI Safety

This is a linkpost for https://bit.ly/cot-monitorability-fragile

Broadcom scales up Ethernet with Tomahawk Ultra for low latency HPC and AI

Broadcom Support for minimum packet size allows streaming of those packets at full bandwidth. That capability is essential for efficient communication in scientific and computational workloads. It is particularly important for scale-up networks where GPU-to-switch-to-GPU communication happens in a single hop. Lossless Ethernet gets an ‘Ultra’ boost Another specific area

F5 streamlines application delivery, security with new AI assistant and code generation service

The AI Assistant can also reduce documentation searches and help accelerate the handling of routine tasks, such as developing traffic configurations and deploying APIs, Ford said. In addition, it can help customers optimize traffic management and app delivery flows by offering real-time AI contextual analytics that can be applied enterprise-wide,

Nvidia to restart H20 exports to China, unveils new export-compliant GPU

China re-entry impact Nvidia’s announcements mark a bid to re-enter the world’s second-largest AI market under tightened US export controls. But this return may not mean business as usual. “Despite Nvidia’s market re-entry, Chinese companies will likely continue diversifying suppliers to strengthen supply chain resilience,” said Prabhu Ram, VP of

Utilities may speed renewable projects under new tax credit timeline: Jefferies

Dive Brief: Utilities are set to accelerate the development of their renewable energy projects in order to qualify for Inflation Reduction Act tax credits within the new one-year safe harbor period set by the Republican megabill that passed earlier this month, according to a July 10 report from investment bank Jefferies. Jefferies anticipates utilities “with renewables-heavy plans” – like Xcel Energy, WEC Energy Group, CMS Energy, and Ameren – “to accelerate projects originally slated for 2030–31 into 2027–28 … While affordability concerns linger, we believe investors are too focused on potential capital pullbacks and not enough on who’s actually accelerating spend.” “The provisions of the new law provide a sufficient path for us to continue delivering new, affordable, clean energy to our customers through the end of the decade,” said Theo Keith, a senior media relations representative at Xcel Energy. “Our well-established planning process ensures we can manage policy changes while working to meet our states’ energy goals and keeping bills as low as possible for our customers.” Dive Insight: “Meeting the unprecedented demand for energy in the U.S. to support our growing economy will require a wide range of energy sources and strengthened infrastructure,” Keith said. “While we supported a longer-term phase-down of the wind and solar tax credits, we recognize that budgets require compromise … we remain focused on an ‘all-of-the-above’ approach for the energy we provide.” The Republican budget megabill, which President Donald Trump signed into law July 4, stipulates that wind and solar projects must start construction within a year of the law’s enactment to qualify for the IRA’s clean electricity production and investment tax credits, or be subjected to an end of 2027 “placed in service” deadline to be eligible. As part of a reported deal with the Freedom Caucus, Trump also issued an executive order

Trump unveils $92B in energy and AI investments for Pennsylvania

President Donald Trump made an appearance at the Pennsylvania Energy and Innovation Summit on Tuesday and announced that companies including Google, Blackstone and FirstEnergy plan to make $92 billion in energy and AI investments in the state. Blackstone will be building and operating “new natural gas-based, combined-cycle generation stations” in a joint venture with PPL Corp “to power data centers under long-term energy services agreements with regulated-like risk profiles that do not expose the companies to merchant energy and capacity price volatility,” said Edison Electric Institute in a release. FirstEnergy Chair, President and CEO Brian Tierney announced at the summit that his utility plans to invest more than $28 billion “systemwide to modernize local distribution systems and strengthen the transmission network. In Pennsylvania, that includes spending $15 billion in the infrastructure enhancements, people, processes, and facilities needed to deliver safe, reliable power.” Thar Casey, CEO of AmberSemi, a developer of power management technologies, including a power conversion solution for AI data centers, attended the summit and said his “first impression from talking to Pennsylvanians is that they’re excited about getting that kind of attention.” “It’s fantastic for the state; it tells me that [Sen. Dave McCormick, R-Pa.] is doing his job,” Casey said. However, he added, he doesn’t only see the announcements as a plus for Pennsylvania, but the U.S. in general. “I had a chance to talk to some very key influential people and speak with them about the efficiency aspect of things, in addition to the focus that they have on power,” he said. “You see it in their eyes when you bring up efficiency — it’s a subject that they’re focused on.” Trump’s announcement was criticized by environmental groups like Evergreen Action, which issued a release saying the president had “unveiled a plan to double down on expensive fossil fuels” after

With Blackstone venture, PPL emerges ‘biggest winner’ from data center summit

Dive Brief: Utility company PPL Corp. is the “biggest winner” from the Pennsylvania Energy and Innovation Summit in Pittsburgh this week with its joint venture with Blackstone Infrastructure to build gas-fired power plants to serve data centers in Pennsylvania and across the PJM Interconnection, Jefferies analysts said Wednesday. PPL and Blackstone are negotiating with multiple potential hyperscale counterparties, according to the analysts, who noted that any new power plants would be operating by 2030 at the earliest. “The joint venture is actively engaged with landowners, natural gas pipeline companies and turbine manufacturers, and has secured multiple land parcels to enable this new generation buildout; however, no [energy services agreements] with hyperscalers have been signed to date,” PPL said Tuesday. Dive Insight: Plans to build gas-fired generation in Pennsylvania comes amid a surge in data center development across the United States, fueled in part by a race to develop artificial intelligence capacity. In PPL Electric Utilities’ service territory in Pennsylvania, there is more than 13 GW of potential data center load in advanced stages of planning, according to PPL. If all those data centers are built, there would be a 6 GW generation shortfall in PPL Electric Utilities’ service territory in the next five to six years, PPL said. It would cost about $15 billion to build enough gas-fired, combined-cycle units to meet the shortfall, PPL said, noting that it expects the power plants would be built by the joint venture, independent power producers and — if legislation is passed to change Pennsylvania law — PPL Electric Utilities. Blackstone said it expects to spend $25 billion on data centers and energy infrastructure in Pennsylvania. QTS, a data center operator backed by Blackstone, has secured land sites across northeastern Pennsylvania for data centers, the private equity firm said. PPL owns 51% of

USA Crude Oil Stocks Drop Week on Week

U.S. commercial crude oil inventories, excluding those in the Strategic Petroleum Reserve (SPR), decreased by 3.9 million barrels from the week ending July 4 to the week ending July 11, the U.S. Energy Information Administration (EIA) highlighted in its latest weekly petroleum status report. That report, which was released on July 16 and included data for the week ending July 11, showed that crude oil stocks, not including the SPR, stood at 422.2 million barrels on July 11, 426.0 million barrels on July 4, and 440.2 million barrels on July 12, 2024. The report highlighted that data may not add up to totals due to independent rounding. Crude oil in the SPR stood at 402.7 million barrels on July 11, 403.0 million barrels on July 4, and 373.7 million barrels on July 12, 2024, the report revealed. Total petroleum stocks – including crude oil, total motor gasoline, fuel ethanol, kerosene type jet fuel, distillate fuel oil, residual fuel oil, propane/propylene, and other oils – stood at 1.658 billion barrels on July 11, the report highlighted. Total petroleum stocks were up 9.0 million barrels week on week and down 11.2 million barrels year on year, the report showed. “At 422.2 million barrels, U.S. crude oil inventories are about eight percent below the five year average for this time of year,” the EIA said in its latest weekly petroleum status report. “Total motor gasoline inventories increased by 3.4 million barrels from last week and are slightly above the five year average for this time of year. Finished gasoline inventories decreased and blending components inventories increased last week,” it added. “Distillate fuel inventories increased by 4.2 million barrels last week and are about 21 percent below the five year average for this time of year. Propane/propylene inventories increased by 4.5 million barrels from

EthosEnergy Bags RISEC Operations and Maintenance Deal

Ethos Energy Group Ltd. (EthosEnergy) has secured a multi-year operations and maintenance deal for the Rhode Island State Energy Center (RISEC), a two-by-one combined-cycle gas turbine power plant outside Providence, Rhode Island. The plant is owned by Shell Energy North America (US) LP. Commissioned in 2002, the plant has a nominal output of 596 megawatts, making it one of the most efficient and reliable energy sources in the region, EthosEnergy noted. EthosEnergy said that under the agreement with RISEC, it will provide a full range of operations and maintenance services, encompassing health, safety, the environment and NERC compliance, along with 24/7 remote monitoring, IT/OT services, human resources and procurement support. “This agreement with Rhode Island State Energy Center is a testament to the strength of our operations and maintenance team and capabilities to manage critical energy infrastructure”, EthosEnergy CEO Ana Amicarella said. “It reflects our commitment to safety, operational excellence, continuous improvement, and innovation, and reinforces our role as a trusted partner in driving reliability and performance as the industry evolves”. Driven by two SGT6-5000F gas turbines and a GE D11 steam turbine, this facility supplies the ISO New England market. Thanks to this new agreement, EthosEnergy said it enhances its footprint in the Northeast. “This award builds on EthosEnergy’s growing momentum of our diverse global O&M fleet and integrated OneEthos portfolio of products and services as the company supports asset owners navigating energy transition, decarbonization goals, and evolving market demands”, Iain O’Brien, SVP Operations of EthosEnergy, added. To contact the author, email [email protected] WHAT DO YOU THINK? Generated by readers, the comments included herein do not reflect the views and opinions of Rigzone. All comments are subject to editorial review. Off-topic, inappropriate or insulting comments will be removed. MORE FROM THIS AUTHOR

SLB Seals ChampionX Takeover

Schlumberger Ltd./NV (SLB) said Wednesday it had completed the acquisition of ChampionX Corp., after the oilfield tech companies resolved competition concerns raised by a few countries. ChampionX shareholders received 0.735 SLB shares per share they held at ChampionX. “With the closing of the transaction, former ChampionX shareholders now own approximately 9 percent of SLB’s outstanding shares of common stock”, SLB confirmed in a statement online. “This strategic acquisition strengthens SLB’s leadership in the production and recovery space”, SLB said. “The integration of ChampionX production chemicals and its complementary artificial lift, digital, and emissions technologies enhances the SLB portfolio, helping to drive performance and extend asset life along the production lifecycle. “The combination of ChampionX’s leading production-focused solutions and customer relationships throughout North America and beyond, with SLB’s strong international presence and history of innovation, will drive significant value for customers and stakeholders globally. “The acquisition also brings together two distinct sets of experts with domain knowledge and customer insights across the entire production and recovery space”. The statement added, “SLB remains on track to return $4 billion to shareholders in 2025 and expects to realize annual pretax synergies from the ChampionX acquisition of approximately $400 million within the first three years post-closing through revenue growth and cost savings”. SLB chief executive Olivier Le Peuch commented, “This acquisition comes at a pivotal time in the industry as our customers increasingly prioritize advancements in production to maximize recovery of oil and gas”. “It extends our capability to provide integrated production solutions and provides another platform for accelerating digital adoption, optimizing production and reducing total cost of ownership for our customers”, Le Peuch added. Regulators in the United States, Canada, Norway and the United Kingdom had held off the merger on risks to market competition. To clear the regulatory hurdles, SLB and ChampionX

Cisco upgrades 400G optical receiver to boost AI infrastructure throughput

“In the data center, what’s really changed in the last year or so is that with AI buildouts, there’s much, much more optics that are part of 400G and 800G. It’s not so much using 10G and 25G optics, which we still sell a ton of, for campus applications. But for AI infrastructure, the 400G and 800G optics are really the dominant optics for that application,” Gartner said. Most of the AI infrastructure builds have been for training models, especially in hyperscaler environments, Gartner said. “I expect, towards the tail end of this year, we’ll start to see more enterprises deploying AI infrastructure for inference. And once they do that, because it has an Nvidia GPU attached to it, it’s going to be a 400G or 800G optic.” Core enterprise applications – such as real-time trading, high-frequency transactions, multi-cloud communications, cybersecurity analytics, network forensics, and industrial IoT – can also utilize the higher network throughput, Gartner said.

Supermicro bets big on 4-socket X14 servers to regain enterprise trust

In April, Dell announced its PowerEdge R470, R570, R670, and R770 servers with Intel Xeon 6 Processors with P-cores, but with single and double-socket servers. Similarly, Lenovo’s ThinkSystem V4 servers are also based on the Intel Xeon 6 processor but are limited to dual socket configurations. The launch of 4-socket servers by Supermicro reflects a growing enterprise need for localized compute that can support memory-bound AI and reduce the complexity of distributed architectures. “The modern 4-socket servers solve multiple pain points that have intensified with GenAI and memory-intensive analytics. Enterprises are increasingly challenged by latency, interconnect complexity, and power budgets in distributed environments. High-capacity, scale-up servers provide an architecture that is more aligned with low-latency, large-model processing, especially where data residency or compliance constraints limit cloud elasticity,” said Sanchit Vir Gogia, chief analyst and CEO at Greyhound Research. “Launching a 4-socket Xeon 6 platform and packaging it within their modular ‘building block’ strategy shows Supermicro is focusing on staying ahead in enterprise and AI data center compute,” said Devroop Dhar, co-founder and MD at Primus Partner. A critical launch after major setbacks Experts peg this to be Supermicro’s most significant product launch since it became mired in governance and regulatory controversies. In 2024, the company lost Ernst & Young, its second auditor in two years, following allegations by Hindenburg Research involving accounting irregularities and the alleged export of sensitive chips to sanctioned entities. Compounding its troubles, Elon Musk’s AI startup xAI redirected its AI server orders to Dell, a move that reportedly cost Supermicro billions in potential revenue and damaged its standing in the hyperscaler ecosystem. Earlier this year, HPE signed a $1 billion contract to provide AI servers for X, a deal Supermicro was also bidding for. “The X14 launch marks a strategic reinforcement for Supermicro, showcasing its commitment

Moving AI workloads off the cloud? A hefty data center retrofit awaits

“If you have a very specific use case, and you want to fold AI into some of your processes, and you need a GPU or two and a server to do that, then, that’s perfectly acceptable,” he says. “What we’re seeing, kind of universally, is that most of the enterprises want to migrate to these autonomous agents and agentic AI, where you do need a lot of compute capacity.” Racks of brand-new GPUs, even without new power and cooling infrastructure, can be costly, and Schneider Electric often advises cost-conscious clients to look at previous-generation GPUs to save money. GPU and other AI-related technology is advancing so rapidly, however, that it’s hard to know when to put down stakes. “We’re kind of in a situation where five years ago, we were talking about a data center lasting 30 years and going through three refreshes, maybe four,” Carlini says. “Now, because it is changing so much and requiring more and more power and cooling you can’t overbuild and then grow into it like you used to.”

My take on the Gartner Magic Quadrant for LAN infrastructure? Highly inaccurate

Fortinet being in the leader quadrant may surprise some given they are best known as a security vendor, but the company has quietly built a broad and deep networking portfolio. I have no issue with them being considered a leader and believe for security conscious companies, Fortinet is a great option. Challenger Cisco is the only company listed as a challenger, and its movement out of the leader quadrant highlights just how inaccurate this document is. There is no vendor that sells more networking equipment in more places than Cisco, and it has led enterprise networking for decades. Several years ago, when it was a leader, I could argue the division of engineering between Meraki and Catalyst could have pushed them out, but it didn’t. So why now? At its June Cisco Live event, the company launched a salvo of innovation including AI Canvas, Cisco AI Assistant, and much more. It’s also continually improved the interoperability between Meraki and Catalyst and announced several new products. AI Canvas is a completely new take, was well received by customers at Cisco Live, and reinvents the concept of AIOps. As I stated above, because of the December cutoff time for information gathering, none of this was included, but that makes Cisco’s representation false. Also, I find this MQ very vague in its “Cautions” segment. As an example, it states: “Cisco’s product strategy isn’t well-aligned with key enterprise needs.” Some details here would be helpful. In my conversations with Cisco, which includes with Chief Product Officer and President Jeetu Patel, the company has reiterated that its strategy is to help customers be AI-ready with products that are easier to deploy and manage, more automated, and with a lower cost to run. That seems well-aligned with customer needs. If Gartner is hearing customers want networks

Equinix, AWS embrace liquid cooling to power AI implementations

With AWS, it deployed In-Row Heat Exchangers (IRHX), a custom-built liquid cooling system designed specifically for servers using Nvidia’s Blackwell GPUs, it’s most powerful but also its hottest running processors used for AI training and inference. The IRHX unit has three components: a water‑distribution cabinet, an integrated pumping unit, and in‑row fan‑coil modules. It uses direct to chip liquid cooling just like the equinox servers, where cold‑plates attached to the chip draw heat from the chips and is cooled by the liquid. The warmed coolant then flows through the coils of heat exchangers, where high‑speed fans Blow on the pipes to cool them, like a car radiator. This type of cooling is nothing new, and there are a few direct to chip liquid cooling solutions on the market from Vertiv, CoolIT, Motivair, and Delta Electronics all sell liquid cooling options. But AWS separates the pumping unit from the fan-coil modules, letting a single pumping system to support large number of fan units. These modular fans can be added or removed as cooling requirements evolve, giving AWS the flexibility to adjust the system per row and site. This led to some concern that Amazon would disrupt the market for liquid cooling, but as a Dell’Oro Group analyst put it, Amazon develops custom technologies for itself and does not go into competition or business with other data center infrastructure companies.

Intel CEO: We are not in the top 10 semiconductor companies

The Q&A session came on the heels of layoffs across the company. Tan was hired in March, and almost immediately he began to promise to divest and reduce non-core assets. Gelsinger had also begun divesting the company of losers, but they were nibbles around the edge. Tan is promising to take an axe to the place. In addition to discontinuing products, the company has outsourced marketing and media relations — for the first time in more than 25 years of covering this company, I have no internal contacts at Intel. Many more workers are going to lose their jobs in coming weeks. So far about 500 have been cut in Oregon and California but many more is expected — as much as 20% of the overall company staff may go, and Intel has over 100,000 employees, according to published reports. Tan believes the company is bloated and too bogged down with layers of management to be reactive and responsive in the same way that AMD and Nvidia are. “The whole process of that (deciding) is so slow and eventually nobody makes a decision,” he is quoted as saying. Something he has decided on is AI, and he seems to have decided to give up. “On training, I think it is too late for us,” Tan said, adding that Nvidia’s position in that market is simply “too strong.” So there goes what sales Gaudi3 could muster. Instead, Tan said Intel will focus on “edge” artificial intelligence, where AI capabilities Are brought to PCs and other remote devices rather than big AI processors in data centers like Nvidia and AMD are doing. “That’s an area that I think is emerging, coming up very big and we want to make sure that we capture,” Tan said.

Microsoft will invest $80B in AI data centers in fiscal 2025

And Microsoft isn’t the only one that is ramping up its investments into AI-enabled data centers. Rival cloud service providers are all investing in either upgrading or opening new data centers to capture a larger chunk of business from developers and users of large language models (LLMs). In a report published in October 2024, Bloomberg Intelligence estimated that demand for generative AI would push Microsoft, AWS, Google, Oracle, Meta, and Apple would between them devote $200 billion to capex in 2025, up from $110 billion in 2023. Microsoft is one of the biggest spenders, followed closely by Google and AWS, Bloomberg Intelligence said. Its estimate of Microsoft’s capital spending on AI, at $62.4 billion for calendar 2025, is lower than Smith’s claim that the company will invest $80 billion in the fiscal year to June 30, 2025. Both figures, though, are way higher than Microsoft’s 2020 capital expenditure of “just” $17.6 billion. The majority of the increased spending is tied to cloud services and the expansion of AI infrastructure needed to provide compute capacity for OpenAI workloads. Separately, last October Amazon CEO Andy Jassy said his company planned total capex spend of $75 billion in 2024 and even more in 2025, with much of it going to AWS, its cloud computing division.

John Deere unveils more autonomous farm machines to address skill labor shortage

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Self-driving tractors might be the path to self-driving cars. John Deere has revealed a new line of autonomous machines and tech across agriculture, construction and commercial landscaping. The Moline, Illinois-based John Deere has been in business for 187 years, yet it’s been a regular as a non-tech company showing off technology at the big tech trade show in Las Vegas and is back at CES 2025 with more autonomous tractors and other vehicles. This is not something we usually cover, but John Deere has a lot of data that is interesting in the big picture of tech. The message from the company is that there aren’t enough skilled farm laborers to do the work that its customers need. It’s been a challenge for most of the last two decades, said Jahmy Hindman, CTO at John Deere, in a briefing. Much of the tech will come this fall and after that. He noted that the average farmer in the U.S. is over 58 and works 12 to 18 hours a day to grow food for us. And he said the American Farm Bureau Federation estimates there are roughly 2.4 million farm jobs that need to be filled annually; and the agricultural work force continues to shrink. (This is my hint to the anti-immigration crowd). John Deere’s autonomous 9RX Tractor. Farmers can oversee it using an app. While each of these industries experiences their own set of challenges, a commonality across all is skilled labor availability. In construction, about 80% percent of contractors struggle to find skilled labor. And in commercial landscaping, 86% of landscaping business owners can’t find labor to fill open positions, he said. “They have to figure out how to do

2025 playbook for enterprise AI success, from agents to evals

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More 2025 is poised to be a pivotal year for enterprise AI. The past year has seen rapid innovation, and this year will see the same. This has made it more critical than ever to revisit your AI strategy to stay competitive and create value for your customers. From scaling AI agents to optimizing costs, here are the five critical areas enterprises should prioritize for their AI strategy this year. 1. Agents: the next generation of automation AI agents are no longer theoretical. In 2025, they’re indispensable tools for enterprises looking to streamline operations and enhance customer interactions. Unlike traditional software, agents powered by large language models (LLMs) can make nuanced decisions, navigate complex multi-step tasks, and integrate seamlessly with tools and APIs. At the start of 2024, agents were not ready for prime time, making frustrating mistakes like hallucinating URLs. They started getting better as frontier large language models themselves improved. “Let me put it this way,” said Sam Witteveen, cofounder of Red Dragon, a company that develops agents for companies, and that recently reviewed the 48 agents it built last year. “Interestingly, the ones that we built at the start of the year, a lot of those worked way better at the end of the year just because the models got better.” Witteveen shared this in the video podcast we filmed to discuss these five big trends in detail. Models are getting better and hallucinating less, and they’re also being trained to do agentic tasks. Another feature that the model providers are researching is a way to use the LLM as a judge, and as models get cheaper (something we’ll cover below), companies can use three or more models to

OpenAI’s red teaming innovations define new essentials for security leaders in the AI era

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More OpenAI has taken a more aggressive approach to red teaming than its AI competitors, demonstrating its security teams’ advanced capabilities in two areas: multi-step reinforcement and external red teaming. OpenAI recently released two papers that set a new competitive standard for improving the quality, reliability and safety of AI models in these two techniques and more. The first paper, “OpenAI’s Approach to External Red Teaming for AI Models and Systems,” reports that specialized teams outside the company have proven effective in uncovering vulnerabilities that might otherwise have made it into a released model because in-house testing techniques may have missed them. In the second paper, “Diverse and Effective Red Teaming with Auto-Generated Rewards and Multi-Step Reinforcement Learning,” OpenAI introduces an automated framework that relies on iterative reinforcement learning to generate a broad spectrum of novel, wide-ranging attacks. Going all-in on red teaming pays practical, competitive dividends It’s encouraging to see competitive intensity in red teaming growing among AI companies. When Anthropic released its AI red team guidelines in June of last year, it joined AI providers including Google, Microsoft, Nvidia, OpenAI, and even the U.S.’s National Institute of Standards and Technology (NIST), which all had released red teaming frameworks. Investing heavily in red teaming yields tangible benefits for security leaders in any organization. OpenAI’s paper on external red teaming provides a detailed analysis of how the company strives to create specialized external teams that include cybersecurity and subject matter experts. The goal is to see if knowledgeable external teams can defeat models’ security perimeters and find gaps in their security, biases and controls that prompt-based testing couldn’t find. What makes OpenAI’s recent papers noteworthy is how well they define using human-in-the-middle

Stay Ahead, Stay ONMINE